Y-mAbs Therapeutics, Inc. Gains 52.28%
Y-mAbs Therapeutics, Inc. (YMAB:NASDAQ) shot up at $5.01, a gain of 52.3%. On Fri, Mar 31, 2023, YMAB:NASDAQ hit a New 2-Week High of $5.01. The stock got featured on our News Catalysts scanner on Thu, Mar 30, 2023 at 05:48 PM in the 'INVESTOR UPDATE' category. From Fri, Mar 17, 2023, the stock recorded 60.00% Up Days and 54.55% Green Days
About Y-mAbs Therapeutics, Inc. (YMAB:NASDAQ)
Y-mAbs Therapeutics Inc is a late-stage clinical biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. Products developed by the company include naxitamab for the treatment of pediatric patients with relapsed or refractory and radiolabeled omburtamab for the treatment of pediatric patients with central nervous system.
Top 10 Gainers:
- Safehold Inc. (SAFE:NYSE), 2884.31%
- Burford Capital Limited (BUR:NYSE), 53.19%
- Y-mAbs Therapeutics, Inc. (YMAB:NASDAQ), 52.28%
- Guardforce AI Co. Limited (GFAI:NASDAQ), 50.32%
- Eastside Distilling, Inc. (EAST:NASDAQ), 45.11%
- Bionomics Limited (BNOX:NASDAQ), 44.44%
- SoundHound AI Inc. (SOUN:NASDAQ), 40.1%
- Calithera Biosciences, Inc. (CALA:NASDAQ), 37.16%
- Pulse Biosciences, Inc. (PLSE:NASDAQ), 35.48%
- Metropolitan Bank Holding Corp. (MCB:NYSE), 33.64%